Mitsubishi UFJ Asset Management Co. Ltd. Invests $352,000 in Xencor, Inc. $XNCR

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Xencor, Inc. (NASDAQ:XNCR) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,881 shares of the biopharmaceutical company’s stock, valued at approximately $352,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Johnson & Johnson purchased a new position in Xencor in the 2nd quarter valued at about $12,043,798,000. Jefferies Financial Group Inc. boosted its stake in shares of Xencor by 620.4% during the 4th quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock worth $11,030,000 after purchasing an additional 620,440 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Xencor by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock worth $109,703,000 after buying an additional 61,692 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Xencor by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock worth $15,613,000 after buying an additional 45,599 shares in the last quarter. Finally, Erste Asset Management GmbH raised its position in shares of Xencor by 26.3% in the fourth quarter. Erste Asset Management GmbH now owns 480,200 shares of the biopharmaceutical company’s stock valued at $7,347,000 after buying an additional 100,000 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts recently issued reports on XNCR shares. Zacks Research raised shares of Xencor from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. JPMorgan Chase & Co. lifted their target price on shares of Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Monday, May 11th. Wedbush boosted their price target on Xencor from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Wall Street Zen raised Xencor from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Xencor presently has an average rating of “Hold” and a consensus price target of $24.86.

Xencor Stock Performance

Shares of XNCR stock opened at $27.80 on Friday. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -12.81 and a beta of 0.85. Xencor, Inc. has a one year low of $7.50 and a one year high of $28.16. The company has a 50 day moving average price of $18.22 and a 200 day moving average price of $14.19.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company had revenue of $51.22 million for the quarter, compared to analyst estimates of $18.89 million. During the same quarter last year, the business earned ($0.41) EPS. Xencor’s revenue for the quarter was up 17.4% on a year-over-year basis. As a group, equities analysts forecast that Xencor, Inc. will post -3 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.